This study aimed to characterize the role of the mitogen-activated protein kinase (MAPK) kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway in cardiac hypertrophy induced by parathyroid hormone (PTH). Various concentrations of rat PTH1-34 were used to induce hypertrophy in neonatal rat ventricular cardiomyocytes, and the effects were compared with control cells and those treated with PD98059, a selective inhibitor of MEK1. Hypertrophy was assessed in terms of cell diameter, atrial natriuretic peptide (ANP) mRNA expression and protein synthesis; the MEK/ERK pathway was assessed by measuring levels of phosphorylated ERK1/2. Treatment with PTH1-34 at 100 nM for 24 h effectively induced cardiac hypertrophy (increased cell diameter, protein synthesis and ANP mRNA expression) and also increased levels of phosphorylated ERK1/2 compared with normal control cells. Treatment with PTH1-34 plus PD98059 significantly attenuated these changes. These results demonstrate that inhibition of the MEK/ERK pathway blocks PTH1-34induced cardiac hypertrophy, suggesting that PTH1-34 might signal through the MAPK pathway to induce hypertrophy in cardiomyocytes.
Introduction
Secondary hyperparathyroidism (SHPT) is a common and serious complication of chronic kidney disease (CKD) resulting from disturbances in the regulation of parathyroid hormone (PTH), calcium, phosphorus and vitamin D. 1 SHPT arises in most patients early in stage 3 of kidney failure. 2, 3 Chronic SHPT is associated with several comorbidities, a major one being left ventricular hypertrophy (LVH), which is the most prevalent cardiac complication observed in patients with CKD. 4, 5 LVH is also a potent risk factor for the development of cardiac arrhythmias, diastolic dysfunction, congestive heart failure and death. 6, 7 A large amount of evidence confirms that LVH in patients with chronic renal failure is related to high blood levels of PTH and PTH is an independent predictor of LVH in patients with CKD. 8, 9 X Liu, R Xie, S Liu Parathyroid hormone and the MEK/ERK pathway Cardiomyocytes have been identified as target cells for PTH. 10, 11 Studies have demonstrated that PTH exerts a hypertrophic effect on adult cardiomyocytes, characterized by an increase in protein synthesis and selective induction of cytosolic creatine kinase. 12 However, the signalling pathways of PTH-induced cardiac hypertrophy remain unknown.
Mitogen-activated protein kinases (MAPKs) are a family of serine/threonine kinases that play a critical role in cellular processes, such as proliferation, differentiation and development. Extracellular signal-regulated kinases 1 and 2 (ERK1/2) are the major isoforms of MAPK that have been well characterized to date and their activation requires phosphorylation by an upstream kinase known as MAPK kinase (MEK). ERK1/2 are activated when cardiomyocytes are exposed to neurohormones, such as endothelin-1 and angiotensin II or mechanical loading. 13 -15 When activated, ERK may integrate signals from multiple receptor systems and common distal signalling pathways, leading to cardiac hypertrophy. 16 However, it remains unknown whether the ERK1/2 pathway participates in PTH-induced cardiac ventricular hypertrophy.
To study the role of ERK1/2 in the hypertrophic responses induced by PTH in ventricular myocytes, PD98059, an inhibitor of MEK1, was used to inhibit the MEK/ERK pathway in cultured neonatal rat cardiomyocytes.
Materials and methods
Cardiomyocytes were prepared from 3-dayold neonatal Wistar rats supplied by the animal experiment centre of Harbin Medical University. This study conformed with Harbin Medical University's guidelines for the care and use of laboratory animals.
PREPARATION OF CARDIOMYOCYTES
Cardiac ventricles were isolated from the rats, perfused twice with phosphate buffered saline (PBS, 0.01 mM, pH 7.2) on ice and finely chopped. Slivers of tissue were digested with 0.08% trypsin (Invitrogen, Carlsbad, CA, USA) and gently shaken at 37°C for 5 min in a water bath; this procedure was repeated eight times. Single cells were harvested by filtration, centrifuged, resuspended in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS; Invitrogen) and 1% nonessential amino acids, and plated onto cell culture dishes for 1.5 h in a humidified incubator (95% air and 5% CO 2 at 37°C) selectively to remove contaminating nonmyocytes. Non-adherent cells were collected and replated onto another cell culture dish in DMEM supplemented with 10% FBS. To prevent growth of non-myocytes, the medium was supplemented with 5′bromodeoxyuridine at a final concentration of 0.1 mM for the first 48 h. On day 3, the cells were rinsed twice with Hank's balanced saline solution to remove the growth media and incubated in serum-free medium. Spontaneously contracting and confluent cells were used for the experiments on day 4 after isolation.
CELL TREATMENTS
Rat PTH1-34 (Sigma, St Louis, MO, USA) was used for the cell treatments. The cells were randomly divided into six groups: (i) normal controls treated with PBS for 24 h; (ii) cells treated with 10 nM PTH1-34 for 24 h; (iii) cells treated with 100 nM PTH1-34 for 24 h; (iv) cells treated with 1 µM PTH1-34 for 24 h; (v) cells treated with 20 µM PD98059 (Promega, Madison, WI, USA) for 1 h and then with 100 nM PTH1-34 for 24 h; and (vi) cells treated with 20 µM PD98059 alone for 25 h.
X Liu, R Xie, S Liu Parathyroid hormone and the MEK/ERK pathway

HYPERTROPHIC RESPONSE
The hypertrophic response of the cultured myocytes after the various treatments was assessed by measuring cell diameter, protein synthesis and atrial natriuretic peptide (ANP) mRNA expression.
For cell diameter, cells were plated on coverslips in a 24-well plate at a density of 1 × 10 4 cells/cm 2 . After treatment, the diameter of the cardiomyocytes in each well was measured with an ocular micrometer in 10 randomly chosen fields.
Protein synthesis was assessed by measuring [ 3 H]leucine incorporation into acid-insoluble cellular material. Cells were plated in 24-well dishes at a density of 1 × 10 5 cells/well, with six wells for each group. After treatment, they were pulsed with 2.5 µCi/ml [ 3 H]leucine (Beijing Atomic Energy Institute, Beijing, China) for 4 h, washed twice with cold PBS and once with 10% trichloroacetic acid (TCA), and extracted with 10% TCA at 4°C for 30 min. Cell residues were rinsed in 95% ethanol, solubilized in 0.25 M NaOH at 4°C for 2 h and then neutralized with 2.5 M HCl plus 1 M Tris-HCl (pH 7.5). Radioactivity was determined using a LS-6500 liquid scintillation counter (Beckmann Coulter, Fullerton, CA, USA).
Expression of ANP was measured by reverse transcription-polymerase chain reaction (RT-PCR). Cells were grown in 60 mm culture dishes at a density of 1 × 10 6 cells/cm 2 . After treatment, total RNA was extracted using RNA TRIzol ® reagent (Invitrogen) and quantified spectrophotometrically. It was then reverse transcribed to synthesize cDNA. β-Actin and ANP were amplified with a RT-PCR kit (Promega), using 10 µg total RNA per sample and specific primers (Invitrogen): ANP sense 5′-ATACAGTGCGGTGTCCAACA-3′, antisense 5-TGCTTTTCAAGAGGGCAGAT-3′, product size 257 base pairs (bp); β-actin sense 5′-CATCTGCTGGAAGGTGGACA-3′, antisense
product size 452 bp. β-Actin and ANP were both amplified as follows, β-actin: 30 cycles of 94°C for 2 min (heat start), 94°C for 30 s (heat denaturation), 57°C for 30 s (reannealing) and 72°C for 30 s (progradation), followed by 72°C for 2 min (further progradation); ANP: 30 cycles of 94°C for 2 min (heat start), 94°C for 30 s (heat denaturation), 48°C for 45 s (reannealing) and 72°C for 40 s (progradation), followed by 72°C 2 min (further progradation). DNA amplifications were detected using 1.2% agarose formaldehyde gel with a PCR molecular weight marker for comparison. The densities of the ANP and internal control β-actin bands were determined by DNA scanner and expressed as the density ratio (ANP/ β-actin). Each experiment was repeated three times.
ERK1/2 EXPRESSION
Expression of ERK1/2 was measured using Western blot analysis. Cells were grown in 60 mm culture dishes at a density of 1 × 10 6 cells/cm 2 . After treatment, the cells were lysed and centrifuged, and total protein concentration was determined. Extracts were boiled in sample buffer and proteins were separated on a 10% sodium dodecyl sulphate-polyacrylamide gel. The separated proteins (30 µg/lane) were transferred to a polyvinylidene difluoride membrane (Millipore, Billerica, MA, USA) and treated with blocking buffer (PBS containing 5% dry milk and 0.2% Tween-20). The membranes were incubated with primary antibody consisting of antiphospho-ERK1/2 (p-ERK1/2) antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) (1:200 dilution) and anti-actin antibody (1:400 Parathyroid hormone and the MEK/ERK pathway G X Liu, R Xie, S Liu Parathyroid hormone and the MEK/ERK pathway dilution) overnight at 4°C and then for 1 h at 37°C with antirabbit and antihorse immunoglobulin G conjugated with alkaline phosphatase (1:1000 dilution) as the secondary antibody. Immune complexes were visualized by 5-bromo-4-chloro-3indolyl phosphate/nitroblue tetrazolium, using a kit from Tian Gen Biotechnology (Beijing, China), according to the manufacturer's instructions. Blots were quantified by UV light scanning densitometry. Each experiment was repeated three times.
STATISTICAL ANALYSIS
Data were expressed as the mean ± SD. Homogeneity of variance was confirmed and differences across multiple conditions were tested by one-way analysis of variance for a completely randomized design. Comparisons between conditions were tested with the Bonferroni test using SPSS ® version 10.0 software (SPSS Inc., Chicago, IL, USA). A P-value < 0.05 was considered to be statistically significant. (Figs 1 -3) .
Results
HYPERTROPHIC RESPONSE
These results indicate that the hypertrophic response of cardiomyocytes to PTH1-34 is dose-dependent, with 100 nM PTH1-34 being the minimum effective dose for inducing cardiac hypertrophy.
Pretreatment of cardiomyocytes with 20 PD98059 alone had no effect compared with normal control cells (Figs 1 -3 ).
ERK1/2 EXPRESSION
Given that the ERK signalling pathway is involved in endothelin-1-and angiotensin IIinduced cardiac hypertrophy, 13, 14 changes in ERK protein expression were investigated in PTH1-34-treated cardiomyocytes. Compared with normal control cells (0 nM PTH1-34), exposure to 100 nM and 1 µM PTH1-34 induced p-ERK1/2 by 1.9-and 2.1-fold, respectively (P < 0.05). Compared with 100 nM PTH1 -34, exposure to 1 µM PTH1-34 increased p-ERK1/2 expression by 0.2-fold (P < 0.05) (Fig. 4) . These results indicate that PTH1-34 activates ERK1/2 in a dosedependent manner, with 100 nM PTH1-34 being the minimum effective dose.
Pretreatment of cardiomyocytes with 20 µM PD98059 significantly reduced the PTH1-34stimulated p-ERK1/2 protein level by 1.0-fold X Liu, R Xie, S Liu Parathyroid hormone and the MEK/ERK pathway compared with the 100 nM PTH group (P < 0.05); 20 µM PD98059 alone had no effect compared with normal control cells ( Fig. 4 ).
Discussion
Intact PTH is encoded on the short arm of chromosome 11 (11p15), comprises 84 amino acids and has a molecular weight of 9225 Da. Amino acids 1 -34 from the Nterminal of PTH is the shortest fragment with complete bioactivity and has been shown to activate protein kinase C and adenylate cyclase in classic PTH target cells. 17 In these cell types, the N-terminal region of the hormone including the first two amino acids stimulates adenylate cyclase, and a midregional part, including amino acids 28 -34, stimulates the activity of protein kinase C. 17 This was the basis on which we used commercially available synthetic rat PTH1-34 in the present study, as it contains the two active domains and can induce a hypertrophic effect in adult cardiomyocytes. 1 Cardiomyocyte hypertrophy produces an 18 At the molecular level, cardiac hypertrophy is characterized by an increase in contractile protein content, induction of the immediate-early genes and re-expression of cardiac embryonic genes (such as ANP, βmyosin heavy chain and skeletal α-actin). 19 These changes depend on the activation of transcription of the corresponding genes and activation of one or more of the intracellular kinase signalling pathways is involved in this. 20, 21 The MAPK cascade is one of the important intracellular pathways involved in cardiac hypertrophic responses induced by humoral stimuli and ERK1/2 has been suggested as having a central role. 22 The activated form of ERK1/2, p-ERK1/2, is phosphorylated at specific threosine and tyrosine residue sites. The present study used Western blot to show that cardiomyocytes treated with 100 nM and 1 µM PTH1-34 for 24 h expressed more p-ERK1/2 than normal cells, suggesting that PTH either affects the activity of certain kinases involved in the expression of ERK1/2 or has a direct effect on the expression of ERK1/2.
Under normal conditions, ANP is mainly synthesized, stored and secreted by cardiac atria, with only little secretion from the ventricles. ANP is regarded as a distinctive index that is increased in ventricles in myocardial hypertrophy. 23 The present study showed that 1-34PTH increased the expression of ANP mRNA, while inhibition of the MEK/ERK pathway by PD98059 attenuated the expression of ANP mRNA in ventricular myocytes. Moreover, pretreatment of cardiomyocytes with PD98059 significantly downregulated the increased [ 3 H]leucine incorporation and attenuated the increased cell diameter induced by PTH1-34. These results indicate that ERK1/2 is involved in the pathway producing the PTH-induced hypertrophic response.
In conclusion, the present study showed that the MEK/ERK1/2 pathway plays a critical role in PTH1-34-induced hypertrophic responses in cultured neonatal rat ventricular myocytes.
